Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms, Plasma Cell 3Myasthenia Gravis 3Neoplasms 2Lymphoma 2Leukemia 2Infections 2Neuromyelitis Optica 1Myelitis, Transverse 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Limbic Encephalitis 1Immunoglobulin Light-chain Amyloidosis 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

Sirolimus 4Everolimus 3Anticonvulsants 2ziprasidone 1perampanel 1enzalutamide 1clevidipine 1brivaracetam 1Zolpidem 1Warfarin 1Vigabatrin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Therapeutic Touch 1Temozolomide 1Surgical Procedures, Operative 1Sulfasalazine 1Spironolactone 1Sevoflurane 1Sevelamer 1Saline Solution 1Rocuronium 1Registries 1Radiotherapy 1Propofol 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Epilepsy × Immunoglobulins, Intravenous × Clear all
NCT01545518 2014-09-01

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Emory University

Phase 2 Terminated
20 enrolled 3 charts

Drug Resistant Epilepsy, Autoimmune Diseases, Epilepsy, Epilepsies, Partial, Autoimmune Diseases of the Nervous System, Limbic Encephalitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡